As European markets experience a rally, buoyed by the U.S.-Iran ceasefire and resulting boost in investor sentiment, attention turns to potential opportunities within this optimistic environment. Identifying undervalued stocks during such periods can be beneficial, as these stocks may offer value through strong fundamentals that are not yet fully reflected in their current market prices.
|
Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|
Teleste Oyj (HLSE:TLT1V) |
€3.50 |
€6.96 |
49.7% |
|
SP Group (CPSE:SPG) |
DKK386.00 |
DKK764.12 |
49.5% |
|
Qrf Comm. VA (ENXTBR:QRF) |
€11.10 |
€22.13 |
49.8% |
|
Multiconsult (OB:MULTI) |
NOK164.60 |
NOK326.08 |
49.5% |
|
Mare Group (BIT:MARE) |
€3.40 |
€6.73 |
49.5% |
|
Maps (BIT:MAPS) |
€2.46 |
€4.91 |
49.9% |
|
Gabriel Holding (CPSE:GABR) |
DKK228.00 |
DKK453.95 |
49.8% |
|
Continental (XTRA:CON) |
€65.16 |
€128.87 |
49.4% |
|
B&S Group (ENXTAM:BSGR) |
€5.85 |
€11.66 |
49.8% |
|
Airbus (ENXTPA:AIR) |
€169.50 |
€336.10 |
49.6% |
Let’s dive into some prime choices out of the screener.
Overview: Ratos AB (publ) is a private equity firm that focuses on buyouts, turnarounds, add-on acquisitions, and middle market transactions, with a market cap of SEK11.29 billion.
Operations: The company’s revenue is segmented into Consumer (SEK4.53 billion), Product Solutions (SEK5.31 billion), Industrial Services (SEK5.12 billion), and Construction & Services (SEK3.93 billion).
Estimated Discount To Fair Value: 24.8%
Ratos AB is trading at SEK 34.22, significantly below its estimated future cash flow value of SEK 45.49, indicating it is undervalued by over 20%. Despite a challenging year with a net loss of SEK 1,743 million in Q4 2025, Ratos’s revenue growth is expected to outpace the Swedish market at an annual rate of 2.5%. However, its dividend yield of 4.09% isn’t well-supported by earnings, and return on equity remains modest at a forecasted 8.2%.
Overview: Vitrolife AB (publ) is a company that offers assisted reproduction products across Europe, the Middle East, Africa, Asia-Pacific, and the Americas with a market cap of SEK13.10 billion.
Operations: Vitrolife generates revenue from its assisted reproduction products across various regions including Europe, the Middle East, Africa, Asia-Pacific, and the Americas.
Estimated Discount To Fair Value: 48.8%
